0000899243-20-026299.txt : 20200924 0000899243-20-026299.hdr.sgml : 20200924 20200924194435 ACCESSION NUMBER: 0000899243-20-026299 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200914 FILED AS OF DATE: 20200924 DATE AS OF CHANGE: 20200924 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ogier Walter C CENTRAL INDEX KEY: 0001344644 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36620 FILM NUMBER: 201196572 MAIL ADDRESS: STREET 1: 8797 BEVERLY BLVD., SUITE 304 CITY: LOS ANGELES STATE: CA ZIP: 90048 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Novus Therapeutics, Inc. CENTRAL INDEX KEY: 0001404281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 19900 MACARTHUR BLVD. STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 949-238-8090 MAIL ADDRESS: STREET 1: 19900 MACARTHUR BLVD. STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 FORMER COMPANY: FORMER CONFORMED NAME: Tokai Pharmaceuticals Inc DATE OF NAME CHANGE: 20070622 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-09-14 0 0001404281 Novus Therapeutics, Inc. NVUS 0001344644 Ogier Walter C C/O NOVUS THERAPEUTICS, INC. 19900 MACARTHUR BLVD., SUITE 550 IRVINE CA 92612 1 0 0 0 Stock Option (Right to Buy) 0.6855 2027-08-31 Common Stock 10415 D Stock Option (Right to Buy) 685.50 2027-08-31 Series X1 Convertible Preferred Stock 461.664 D Stock Option (Right to Buy) 0.495 2030-01-28 Common Stock 19190 D Stock Option (Right to Buy) 495.00 2030-01-28 Series X1 Convertible Preferred Stock 850.662 D Stock Option (Right to Buy) 0.3808 2030-09-07 Common Stock 68791 D Stock Option (Right to Buy) 380.80 2030-09-07 Series X1 Convertible Preferred Stock 3049.408 D The option is fully vested. Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer. Ex. 24 - Power of Attorney /s/ Ryan A. Murr, as attorney-in-fact for Walter Ogier 2020-09-24 EX-24 2 attachment1.htm EX-24 DOCUMENT

                               POWER OF ATTORNEY

    Know all by these presents, that the undersigned hereby constitutes and
appoints Jon Kuwahara and Ryan A. Murr, with full power of substitution, the
undersigned's true and lawful attorney-in-fact to:

    (1)  prepare, execute in the undersigned's name and on the undersigned's
         behalf, and submit to the U.S. Securities and Exchange Commission (the
         "SEC") a Form ID, including amendments thereto, and any other documents
         necessary or appropriate to obtain codes, passwords and passphrases
         enabling the undersigned to make electronic filings with the SEC of
         reports required by the Securities Exchange Act of 1934 or any rule or
         regulation of the SEC;

    (2)  execute for and on behalf of the undersigned, in the undersigned's
         capacity as an officer and/or director of Novus Therapeutics, Inc. (the
         "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the
         Securities Exchange Act of 1934 and the rules thereunder;

    (3)  do and perform any and all acts for and on behalf of the undersigned
         which may be necessary or desirable to complete and execute any such
         Form 3, 4, or 5, complete and execute any amendment or amendments
         thereto, and timely file such form with the SEC and any securities
         exchange or similar authority; and

    (4)  take any other action of any type whatsoever in connection with the
         foregoing which, in the opinion of such attorney-in-fact, may be of
         benefit to, in the best interest of, or legally required by, the
         undersigned, it being understood that the documents executed by such
         attorney-in-fact on behalf of the undersigned pursuant to this Power of
         Attorney shall be in such form and shall contain such terms and
         conditions as such attorney-in-fact may approve in such attorney-in-
         fact's discretion.

    The undersigned hereby grants to such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned also ratifies hereby any action previously taken by
each attorney-in-fact that would have been authorized by this power of attorney
if it has been in effect at the time such action was taken. The undersigned
acknowledges that the foregoing attorney-in-fact, in serving in such capacity at
the request of the undersigned, is not assuming, nor is the Company assuming,
any of the undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934, as amended.

    This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorney-in-fact.

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 16th day of September 2020.



                                        /s/ Walter Ogier
                                        ------------------------------
                                        Signature

                                        Walter Ogier
                                        ------------------------------
                                        Print Name